Selected research
Industry Research
Biologics Monoclonal Antibodies Drug Industry Research Report 2026
Market perspective
The global Biologics Monoclonal Antibodies Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biologics Monoclonal Antibodies Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biologics Monoclonal Antibodies Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biologics Monoclonal Antibodies Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biologics Monoclonal Antibodies Drug include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biologics Monoclonal Antibodies Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biologics Monoclonal Antibodies Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biologics Monoclonal Antibodies Drug Market by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Biogen
Amgen
AbbVie
Sobi
Innovent Biologics
Biologics Monoclonal Antibodies Drug Segment by Type
Trastuzumab
Rituximab
Infliximab
Adalimumab
Other
Biologics Monoclonal Antibodies Drug Segment by Application
Cancer
Autoimmune Disease
Other
Biologics Monoclonal Antibodies Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics Monoclonal Antibodies Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics Monoclonal Antibodies Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics Monoclonal Antibodies Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biologics Monoclonal Antibodies Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Trastuzumab
- Rituximab
- Infliximab
- Adalimumab
- Other
Applications
- Cancer
- Autoimmune Disease
- Other
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Eli Lilly
- Pfizer
- Biogen
- Amgen
- AbbVie
- Sobi
- Innovent Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biologics Monoclonal Antibodies Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Trastuzumab
- 2.2.3 Rituximab
- 2.2.4 Infliximab
- 2.2.5 Adalimumab
- 2.2.6 Other
- 2.3 Biologics Monoclonal Antibodies Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Autoimmune Disease
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Biologics Monoclonal Antibodies Drug Breakdown Data by Type
- 3.1 Global Biologics Monoclonal Antibodies Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Type (2027-2032)
4 Biologics Monoclonal Antibodies Drug Breakdown Data by Application
- 4.1 Global Biologics Monoclonal Antibodies Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biologics Monoclonal Antibodies Drug Market Perspective (2021-2032)
- 5.2 Global Biologics Monoclonal Antibodies Drug Growth Trends by Region
- 5.2.1 Global Biologics Monoclonal Antibodies Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biologics Monoclonal Antibodies Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Biologics Monoclonal Antibodies Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Biologics Monoclonal Antibodies Drug Market Dynamics
- 5.3.1 Biologics Monoclonal Antibodies Drug Industry Trends
- 5.3.2 Biologics Monoclonal Antibodies Drug Market Drivers
- 5.3.3 Biologics Monoclonal Antibodies Drug Market Challenges
- 5.3.4 Biologics Monoclonal Antibodies Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biologics Monoclonal Antibodies Drug Players by Revenue
- 6.1.1 Global Top Biologics Monoclonal Antibodies Drug Players by Revenue (2021-2026)
- 6.1.2 Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Biologics Monoclonal Antibodies Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biologics Monoclonal Antibodies Drug Head Office and Area Served
- 6.4 Global Biologics Monoclonal Antibodies Drug Players, Product Type & Application
- 6.5 Global Biologics Monoclonal Antibodies Drug Manufacturers Established Date
- 6.6 Global Biologics Monoclonal Antibodies Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biologics Monoclonal Antibodies Drug Market Size (2021-2032)
- 7.2 North America Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biologics Monoclonal Antibodies Drug Market Size by Country (2021-2026)
- 7.4 North America Biologics Monoclonal Antibodies Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biologics Monoclonal Antibodies Drug Market Size (2021-2032)
- 8.2 Europe Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biologics Monoclonal Antibodies Drug Market Size by Country (2021-2026)
- 8.4 Europe Biologics Monoclonal Antibodies Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biologics Monoclonal Antibodies Drug Market Size (2021-2032)
- 10.2 South America Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biologics Monoclonal Antibodies Drug Market Size by Country (2021-2026)
- 10.4 South America Biologics Monoclonal Antibodies Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.1.4 Sanofi Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.2.4 Johnson & Johnson Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.3.4 Novartis Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck
- 12.4.1 Merck Company Information
- 12.4.2 Merck Business Overview
- 12.4.3 Merck Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.4.4 Merck Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.4.5 Merck Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.5.4 Roche Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 Eli Lilly
- 12.6.1 Eli Lilly Company Information
- 12.6.2 Eli Lilly Business Overview
- 12.6.3 Eli Lilly Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.6.4 Eli Lilly Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.6.5 Eli Lilly Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.7.4 Pfizer Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 Biogen
- 12.8.1 Biogen Company Information
- 12.8.2 Biogen Business Overview
- 12.8.3 Biogen Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.8.4 Biogen Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.8.5 Biogen Recent Developments
- 12.9 Amgen
- 12.9.1 Amgen Company Information
- 12.9.2 Amgen Business Overview
- 12.9.3 Amgen Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.9.4 Amgen Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.9.5 Amgen Recent Developments
- 12.10 AbbVie
- 12.10.1 AbbVie Company Information
- 12.10.2 AbbVie Business Overview
- 12.10.3 AbbVie Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.10.4 AbbVie Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.10.5 AbbVie Recent Developments
- 12.11 Sobi
- 12.11.1 Sobi Company Information
- 12.11.2 Sobi Business Overview
- 12.11.3 Sobi Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.11.4 Sobi Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.11.5 Sobi Recent Developments
- 12.12 Innovent Biologics
- 12.12.1 Innovent Biologics Company Information
- 12.12.2 Innovent Biologics Business Overview
- 12.12.3 Innovent Biologics Revenue in Biologics Monoclonal Antibodies Drug Business (2021-2026)
- 12.12.4 Innovent Biologics Biologics Monoclonal Antibodies Drug Product Portfolio
- 12.12.5 Innovent Biologics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst